Connection

Michael Gold to Defibrillators, Implantable

This is a "connection" page, showing publications Michael Gold has written about Defibrillators, Implantable.
Connection Strength

32.598
  1. Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study. Heart Rhythm. 2022 Dec; 19(12):1993-2001.
    View in: PubMed
    Score: 0.616
  2. Can We Treat an Older Patient With a New Trick? J Am Coll Cardiol. 2022 03 22; 79(11):1060-1062.
    View in: PubMed
    Score: 0.600
  3. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.582
  4. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
    View in: PubMed
    Score: 0.544
  5. 1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The?Subcutaneous?ICD?Post?Approval Study. JACC Clin Electrophysiol. 2020 11; 6(12):1537-1550.
    View in: PubMed
    Score: 0.539
  6. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008631.
    View in: PubMed
    Score: 0.535
  7. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
    View in: PubMed
    Score: 0.527
  8. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
    View in: PubMed
    Score: 0.522
  9. Editorial commentary: The subcutaneous ICD: An expanding niche or the future of implantable defibrillators? Trends Cardiovasc Med. 2020 08; 30(6):385-386.
    View in: PubMed
    Score: 0.508
  10. Electrocardiogram in Cardiac?Resynchronization Therapy: Is Non-Left Bundle Branch Block an Oversimplification? J Am Coll Cardiol. 2019 06 25; 73(24):3100-3101.
    View in: PubMed
    Score: 0.497
  11. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
    View in: PubMed
    Score: 0.492
  12. A Substernal Defibrillator Lead?With?Pacing Capability: Another Tool in the Toolbox? JACC Clin Electrophysiol. 2019 02; 5(2):197-198.
    View in: PubMed
    Score: 0.483
  13. Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. Pacing Clin Electrophysiol. 2018 07; 41(7):807-816.
    View in: PubMed
    Score: 0.462
  14. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
    View in: PubMed
    Score: 0.453
  15. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
    View in: PubMed
    Score: 0.429
  16. ICD Utilization: Can We Select the Right Patients? JACC Clin Electrophysiol. 2017 03; 3(3):299-301.
    View in: PubMed
    Score: 0.424
  17. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.419
  18. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.402
  19. Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. Heart Rhythm. 2016 08; 13(8):1631-5.
    View in: PubMed
    Score: 0.400
  20. Safety and Efficacy of the Subcutaneous Implantable Defibrillator. J Am Coll Cardiol. 2016 Feb 02; 67(4):445-454.
    View in: PubMed
    Score: 0.393
  21. Biventricular pacemaker/defibrillators versus biventricular pacemakers in patients with non-ischemic cardiomyopathy. Card Electrophysiol Clin. 2015 Sep; 7(3):455-9.
    View in: PubMed
    Score: 0.376
  22. Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. J Am Coll Cardiol. 2015 Jun 23; 65(24):2581-2588.
    View in: PubMed
    Score: 0.373
  23. Clinical experience with subcutaneous implantable cardioverter-defibrillators. Nat Rev Cardiol. 2015 Jul; 12(7):398-405.
    View in: PubMed
    Score: 0.372
  24. A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol. 2015 Apr; 26(4):417-423.
    View in: PubMed
    Score: 0.367
  25. Preclinical evaluation of implantable cardioverter-defibrillator developed for magnetic resonance imaging use. Heart Rhythm. 2015 Mar; 12(3):631-638.
    View in: PubMed
    Score: 0.363
  26. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014 Aug; 11(8):1352-8.
    View in: PubMed
    Score: 0.346
  27. Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
    View in: PubMed
    Score: 0.343
  28. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1236-44; discussion 1244-5.
    View in: PubMed
    Score: 0.338
  29. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.335
  30. How many transvenous coils are optimal for defibrillators: one, two, or none? Heart Rhythm. 2013 Jul; 10(7):977-8.
    View in: PubMed
    Score: 0.324
  31. Influence of intracardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf trial. Circ Arrhythm Electrophysiol. 2013 Apr; 6(2):272-8.
    View in: PubMed
    Score: 0.322
  32. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013 Apr 15; 111(8):1165-8.
    View in: PubMed
    Score: 0.318
  33. Is defibrillation testing of ICDs necessary? Nat Rev Cardiol. 2012 Nov; 9(11):618-9.
    View in: PubMed
    Score: 0.312
  34. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):587-93.
    View in: PubMed
    Score: 0.304
  35. Hemoglobin spectroscopy to evaluate hemodynamic function during tachycardias: the future of ICD discrimination algorithms? Heart Rhythm. 2012 Oct; 9(10):1592-3.
    View in: PubMed
    Score: 0.304
  36. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):468-74.
    View in: PubMed
    Score: 0.302
  37. Interactions between a left ventricular assist device and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2012 Sep; 35(9):e272-3.
    View in: PubMed
    Score: 0.301
  38. Acute performance of a right ventricular automatic pacing threshold algorithm for implantable defibrillators. Pacing Clin Electrophysiol. 2012 Mar; 35(3):259-68.
    View in: PubMed
    Score: 0.294
  39. Pre-discharge defibrillation testing: clinically important or obsolete? Europace. 2012 Feb; 14(2):155-6.
    View in: PubMed
    Score: 0.293
  40. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):359-66.
    View in: PubMed
    Score: 0.292
  41. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
    View in: PubMed
    Score: 0.291
  42. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.289
  43. Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy. Heart Fail Clin. 2011 Apr; 7(2):241-50, ix.
    View in: PubMed
    Score: 0.281
  44. Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul; 8(7):1008-13.
    View in: PubMed
    Score: 0.278
  45. To the Editor: Optimizing right ventricular lead position for defibrillation. Heart Rhythm. 2012 Dec; 9(12):e26-7.
    View in: PubMed
    Score: 0.277
  46. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
    View in: PubMed
    Score: 0.274
  47. Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials. Curr Cardiol Rep. 2010 Sep; 12(5):367-73.
    View in: PubMed
    Score: 0.270
  48. Response to Coceani: Has CRT earned a class I recommendation? Circ Heart Fail. 2010 Jul; 3(4):559-60.
    View in: PubMed
    Score: 0.266
  49. Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm. 2010 Nov; 7(11):1561-6.
    View in: PubMed
    Score: 0.266
  50. Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Curr Opin Cardiol. 2010 May; 25(3):268-75.
    View in: PubMed
    Score: 0.263
  51. Defibrillation threshold testing at implantation: can we predict the patient with a high defibrillation threshold? Europace. 2010 Mar; 12(3):309-10.
    View in: PubMed
    Score: 0.259
  52. Implantable device use in systolic heart failure: lessons learned from IMPROVE HF. Heart Rhythm. 2009 Dec; 6(12):1735-6.
    View in: PubMed
    Score: 0.252
  53. Defibrillation testing at ICD implantation: are we asking the wrong question? Pacing Clin Electrophysiol. 2009 May; 32(5):567-9.
    View in: PubMed
    Score: 0.246
  54. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
    View in: PubMed
    Score: 0.243
  55. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.238
  56. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm. 2008 Mar; 5(3):394-9.
    View in: PubMed
    Score: 0.223
  57. Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol. 2007 Jul 15; 100(2):243-6.
    View in: PubMed
    Score: 0.215
  58. Sudden cardiac death: the role of risk stratification. Am Heart J. 2007 Apr; 153(4 Suppl):25-33.
    View in: PubMed
    Score: 0.213
  59. Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
    View in: PubMed
    Score: 0.213
  60. The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2006 Jul; 17(7):749-53.
    View in: PubMed
    Score: 0.202
  61. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. J Cardiovasc Electrophysiol. 2006 Jun; 17(6):617-20.
    View in: PubMed
    Score: 0.201
  62. Coronary sinus electrode does not reduce atrial defibrillation thresholds. Heart Rhythm. 2006 Jun; 3(6):647-52.
    View in: PubMed
    Score: 0.197
  63. Improved defibrillation efficacy with an ascending ramp waveform in humans. Heart Rhythm. 2005 Apr; 2(4):388-94.
    View in: PubMed
    Score: 0.185
  64. Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. Heart Rhythm. 2005 Jan; 2(1):49-54.
    View in: PubMed
    Score: 0.182
  65. Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
    View in: PubMed
    Score: 0.176
  66. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol. 2004 Feb; 27(2):218-20.
    View in: PubMed
    Score: 0.171
  67. Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. J Interv Card Electrophysiol. 2003 Dec; 9(3):391-6.
    View in: PubMed
    Score: 0.169
  68. Effectiveness of rapid atrial pacing for termination of drug refractory atrial fibrillation: results of a dual chamber implantable cardioverter defibrillator trial. Card Electrophysiol Rev. 2003 Dec; 7(4):341-4.
    View in: PubMed
    Score: 0.169
  69. Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol. 2003 Oct; 14(10):1036-40.
    View in: PubMed
    Score: 0.167
  70. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
    View in: PubMed
    Score: 0.159
  71. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 2003 Jan; 26(1P2):483-6.
    View in: PubMed
    Score: 0.158
  72. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. J Cardiovasc Electrophysiol. 2002 Nov; 13(11):1092-7.
    View in: PubMed
    Score: 0.157
  73. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation. 2002 Apr 30; 105(17):2043-8.
    View in: PubMed
    Score: 0.151
  74. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.150
  75. Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 2002 Apr; 13(4):332-5.
    View in: PubMed
    Score: 0.150
  76. Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. Am J Cardiol. 2001 Dec 01; 88(11):1308-11.
    View in: PubMed
    Score: 0.147
  77. The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studies. Heart Rhythm. 2022 04; 19(4):595-603.
    View in: PubMed
    Score: 0.147
  78. Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart?Failure Status. JACC Clin Electrophysiol. 2022 02; 8(2):182-193.
    View in: PubMed
    Score: 0.147
  79. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
    View in: PubMed
    Score: 0.146
  80. Positive Psychotherapy Improves Cardiac Electrical Stability and Mood in ICD Patients: PAM-ICD Trial Results. Psychosom Med. 2021 04 01; 83(3):300-301.
    View in: PubMed
    Score: 0.140
  81. Implantable cardiac defibrillators. Med Clin North Am. 2001 Mar; 85(2):343-67, xi.
    View in: PubMed
    Score: 0.140
  82. Outcomes of two versus three incision techniques: Results from the subcutaneous ICD post-approval study. J Cardiovasc Electrophysiol. 2021 03; 32(3):792-801.
    View in: PubMed
    Score: 0.139
  83. Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. Pacing Clin Electrophysiol. 2001 Jan; 24(1):70-4.
    View in: PubMed
    Score: 0.138
  84. Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Can J Cardiol. 2021 05; 37(5):803-809.
    View in: PubMed
    Score: 0.137
  85. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1981-5.
    View in: PubMed
    Score: 0.136
  86. Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
    View in: PubMed
    Score: 0.136
  87. ICD therapy in the new millennium. Cardiol Clin. 2000 May; 18(2):375-89.
    View in: PubMed
    Score: 0.132
  88. Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. J Comp Eff Res. 2020 04; 9(5):375-385.
    View in: PubMed
    Score: 0.130
  89. Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):21-4.
    View in: PubMed
    Score: 0.129
  90. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):25-9.
    View in: PubMed
    Score: 0.129
  91. Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Am J Cardiol. 1999 Sep 01; 84(5):555-7.
    View in: PubMed
    Score: 0.126
  92. Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. J Am Coll Cardiol. 1999 Aug; 34(2):358-62.
    View in: PubMed
    Score: 0.125
  93. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. Am Heart J. 1999 Jul; 138(1 Pt 1):133-6.
    View in: PubMed
    Score: 0.124
  94. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 04; 12(4):e006665.
    View in: PubMed
    Score: 0.122
  95. The effect of shock configuration and delivered energy on defibrillation impedance. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):165-8.
    View in: PubMed
    Score: 0.120
  96. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):179-82.
    View in: PubMed
    Score: 0.120
  97. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol. 1998 Dec; 2(4):345-9.
    View in: PubMed
    Score: 0.119
  98. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials. J Interv Card Electrophysiol. 1998 Dec; 2(4):367-70.
    View in: PubMed
    Score: 0.119
  99. Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm. 2019 04; 16(4):581-587.
    View in: PubMed
    Score: 0.119
  100. Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
    View in: PubMed
    Score: 0.118
  101. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Apr; 9(4):350-4.
    View in: PubMed
    Score: 0.114
  102. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Mar; 9(3):240-4.
    View in: PubMed
    Score: 0.113
  103. Lead system optimization for transvenous defibrillation. Am J Cardiol. 1997 Nov 01; 80(9):1163-7.
    View in: PubMed
    Score: 0.111
  104. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol. 1997 Oct 15; 80(8):1098-100.
    View in: PubMed
    Score: 0.110
  105. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol. 1997 Oct 01; 80(7):960-2.
    View in: PubMed
    Score: 0.110
  106. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
    View in: PubMed
    Score: 0.110
  107. Permanent pacing from the coronary sinus in a patient with an implantable defibrillator. Pacing Clin Electrophysiol. 1997 Sep; 20(9 Pt 1):2286-7.
    View in: PubMed
    Score: 0.109
  108. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997 Jul; 30(1):233-6.
    View in: PubMed
    Score: 0.108
  109. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
    View in: PubMed
    Score: 0.108
  110. Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. Pacing Clin Electrophysiol. 1997 Jun; 20(6):1682-5.
    View in: PubMed
    Score: 0.108
  111. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May 01; 38(17):1339-1344.
    View in: PubMed
    Score: 0.107
  112. Predictors of short-term clinical response to cardiac resynchronization therapy. Eur J Heart Fail. 2017 08; 19(8):1056-1063.
    View in: PubMed
    Score: 0.106
  113. Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. Am J Cardiol. 1997 Feb 15; 79(4):502-5.
    View in: PubMed
    Score: 0.105
  114. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
    View in: PubMed
    Score: 0.105
  115. Economic Value and Cost-Effectiveness of?Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 03; 5(3):204-212.
    View in: PubMed
    Score: 0.105
  116. Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing Clin Electrophysiol. 1997 Jan; 20(1 Pt 2):208-11.
    View in: PubMed
    Score: 0.105
  117. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.104
  118. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996 Nov 01; 28(5):1278-82.
    View in: PubMed
    Score: 0.103
  119. Magnetic Resonance Imaging-Conditional External Cardiac Defibrillator: Expanding Access and Safety During Magnetic Resonance Imaging. Circ Cardiovasc Imaging. 2016 10; 9(10).
    View in: PubMed
    Score: 0.103
  120. Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
    View in: PubMed
    Score: 0.102
  121. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol. 1996 Sep 01; 78(5):540-3.
    View in: PubMed
    Score: 0.102
  122. Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
    View in: PubMed
    Score: 0.102
  123. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol. 1996 Aug 01; 78(3):313-6.
    View in: PubMed
    Score: 0.102
  124. Transvenous defibrillation lead systems. J Cardiovasc Electrophysiol. 1996 Jun; 7(6):570-80.
    View in: PubMed
    Score: 0.100
  125. Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
    View in: PubMed
    Score: 0.100
  126. Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients (PAM-ICD): Rationale and Design of an RCT Currently Underway. Pacing Clin Electrophysiol. 2016 May; 39(5):458-70.
    View in: PubMed
    Score: 0.099
  127. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
    View in: PubMed
    Score: 0.098
  128. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.095
  129. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE?Study?and?EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28; 65(16):1605-1615.
    View in: PubMed
    Score: 0.093
  130. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. Pacing Clin Electrophysiol. 1995 Mar; 18(3 Pt 1):478-81.
    View in: PubMed
    Score: 0.092
  131. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 Jul 01; 130(1):94-125.
    View in: PubMed
    Score: 0.087
  132. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Heart Rhythm. 2014 Jul; 11(7):1271-303.
    View in: PubMed
    Score: 0.087
  133. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol. 2014 Sep 16; 64(11):1143-77.
    View in: PubMed
    Score: 0.087
  134. Implantable cardiovertor/defibrillator placement in a patient with amiodarone pulmonary toxicity under thoracic epidural anesthesia. Anesthesiology. 1993 Sep; 79(3):608-11.
    View in: PubMed
    Score: 0.083
  135. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
    View in: PubMed
    Score: 0.083
  136. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013 Apr; 24(4):381-7.
    View in: PubMed
    Score: 0.080
  137. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.079
  138. Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. Heart Rhythm. 2012 Oct; 9(10):1667-73.
    View in: PubMed
    Score: 0.076
  139. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
    View in: PubMed
    Score: 0.074
  140. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12; 366(2):120-9.
    View in: PubMed
    Score: 0.074
  141. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.072
  142. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management: executive summary this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm. 2011 Jul; 8(7):e1-18.
    View in: PubMed
    Score: 0.071
  143. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm. 2011 Jul; 8(7):1114-54.
    View in: PubMed
    Score: 0.071
  144. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.070
  145. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.068
  146. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.068
  147. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.063
  148. Role of transesophageal echocardiography among patients with atrial fibrillation undergoing electrophysiology testing. Am J Cardiol. 2009 Nov 01; 104(9):1256-8.
    View in: PubMed
    Score: 0.063
  149. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
    View in: PubMed
    Score: 0.059
  150. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. Cardiol Clin. 2008 Aug; 26(3):419-31, vi-vii.
    View in: PubMed
    Score: 0.058
  151. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale. Am Heart J. 2007 Jan; 153(1):7-13.
    View in: PubMed
    Score: 0.052
  152. Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
    View in: PubMed
    Score: 0.047
  153. Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
    View in: PubMed
    Score: 0.045
  154. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
    View in: PubMed
    Score: 0.043
  155. Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
    View in: PubMed
    Score: 0.041
  156. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
    View in: PubMed
    Score: 0.041
  157. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2003 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.040
  158. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.038
  159. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
    View in: PubMed
    Score: 0.038
  160. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2002 Jan; 17(1):1-5.
    View in: PubMed
    Score: 0.037
  161. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
    View in: PubMed
    Score: 0.035
  162. Correlation waveform analysis of the atrial signal: the shape of things to come? J Cardiovasc Electrophysiol. 2001 Feb; 12(2):150-2.
    View in: PubMed
    Score: 0.035
  163. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001 Jan; 141(1):92-8.
    View in: PubMed
    Score: 0.034
  164. Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol. 1999 Apr; 22(4 Pt 1):665-7.
    View in: PubMed
    Score: 0.031
  165. The effect of delivered energy on defibrillation shock impedance. J Interv Card Electrophysiol. 1998 Sep; 2(3):273-7.
    View in: PubMed
    Score: 0.029
  166. Lidocaine-related increase in defibrillation threshold. Anesth Analg. 1997 Aug; 85(2):299-300.
    View in: PubMed
    Score: 0.027
  167. The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. Am J Cardiol. 2015 Oct 15; 116 Suppl 1:S1-9.
    View in: PubMed
    Score: 0.024
  168. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.021
  169. Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
    View in: PubMed
    Score: 0.017
  170. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
    View in: PubMed
    Score: 0.014
  171. Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J. 2007 Jun; 153(6):951-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.